Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC ...Middle East

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, and...

Hence then, the article about cardiff oncology presents findings from its expanded access program highlighting the clinical benefit of onvansertib in heavily pretreated patients with metastatic kras mutated mcrc was published today ( Saturday 10/04/2021 - 04:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC )

Also on site :

• DoE Deletes Webpage Instructing People To Lower Thermostat to 78
• Ukraine-Russia war latest: Putin and Zelensky vow to escalate fighting after deadliest strike on Kyiv this year
• AI-Created Indian Musical Microdrama ‘Mohini – Khud Se Pyaar’ Unveils Debut Track ‘Angaat Aalay Ka’ (EXCLUSIVE)